Patents Assigned to Pfizer Inc.
-
Publication number: 20240124439Abstract: The invention relates to imidazopyridines of Formula (I) and pharmaceutically acceptable salts thereof, wherein R0 to R5 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.Type: ApplicationFiled: December 13, 2021Publication date: April 18, 2024Applicant: Pfizer Inc.Inventors: Scott William Bagley, Agustin Casimiro-Garcia, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Katherine Lin Lee, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
-
Publication number: 20240122865Abstract: The present disclosure provides methods of protecting ribonucleic acid (RNA) from degradation under certain conditions by contacting the RNA with an amino acid. The present disclosure also provides compositions comprising such amino acid(s) and RNA.Type: ApplicationFiled: February 15, 2022Publication date: April 18, 2024Applicant: Pfizer Inc.Inventors: Justin Leigh Bellenger, Ye Che, Miguel Angel Garcia, Lei Hu, Mark Carl Noe, Shuai Shi
-
Patent number: 11958901Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.Type: GrantFiled: November 20, 2020Date of Patent: April 16, 2024Assignees: Pfizer Inc., The Regents of the University of CaliforniaInventors: Rachel Groth, William Brian Snyder, Xianjun Cao, Robert Joseph Dunn, Joseph Dal Porto, Michael Karin
-
Publication number: 20240116937Abstract: This invention relates to crystalline free base forms of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, and to compositions and therapeutic uses thereof.Type: ApplicationFiled: July 8, 2021Publication date: April 11, 2024Applicant: Pfizer Inc.Inventors: Wesley Dewitt Clark, Klimentina Dimitrova Pencheva
-
Patent number: 11952597Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.Type: GrantFiled: July 7, 2020Date of Patent: April 9, 2024Assignee: Pfizer Inc.Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
-
Patent number: 11954851Abstract: A diagnostic system performs disease diagnostic tests using at least an optical property modifying device and a mobile device. A user provides a biological sample from a patient to the optical property modifying device that reacts with a reagent in one or more reaction chambers of the device. The user captures one or more images of the one or more reaction chambers using an optical sensor of the mobile device. The diagnostic system can determine a quality level of the images based on factors such as skew, scale, focusing, shadowing, or white-balancing. Based on an analysis of the captured image, the diagnostic system can determine a test result of a disease diagnostic test for the patient. The diagnostic system may communicate the test result, as well as instructions for the disease diagnostic test, to the user via the mobile device.Type: GrantFiled: June 30, 2021Date of Patent: April 9, 2024Assignee: Pfizer Inc.Inventors: Ivan Krastev Dimov, Frank B. Myers, III, John Robert Waldeisen, Debkishore Mitra
-
Publication number: 20240109915Abstract: A compound having the structures: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein; R selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy and —(CH2)m—W, where W is C3-C8 cycloalkyl, bicycloalkyl, bridged bicycloalkyl, phenyl, 5- or 6-membered heteroaryl or heterocyclic containing one, two or three heteroatoms selected from the group consisting of N, S and O atoms; wherein each of said alkyl, cycloalkyl, alkoxy, heterocyclic, phenyl, naphthyl or heteroaryl may be unsubstituted or substituted by phenyl, halo, cyano, deuterium, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, —SO2—R?, —CONR?R?, NR?COR?, —NR?CONR?R?, —NR?CO2R?, —(CH2)n—SO2—R?, —NHSO2—R?, —NR?SO2—R?, —SO2NR?R?, NR?R? or SR? where R? and R? are independently H, C1-C6 alkyl or C3-C8 cycloalkyl; R1 selected from the group consisting of phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing one, two, three or four heteroatoms seType: ApplicationFiled: July 26, 2023Publication date: April 4, 2024Applicant: Pfizer Inc.Inventors: Scott William Bagley, Andrea Nicole Bootsma, Chulho Choi, Robert Lee Dow, David James Edmonds, Carmen Noemi Garcia-Irizarry, Brian Stephen Gerstenberger, Gajendra Ingle, Jessica Gloria Katherine O'Brien, Mihir Dineshkumar Parikh, Gwenaella Christine Rescourio, Daniel Copley Schmitt
-
Patent number: 11939367Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.Type: GrantFiled: March 1, 2021Date of Patent: March 26, 2024Assignees: Sanford Burnham Prebys Medical Discovery Institute, Pfizer Inc.Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
-
Publication number: 20240093248Abstract: The invention relates to a method of cell culture where the cells are modified to reduce the level of synthesis of growth and/or productivity inhibitors by the cell. The invention also relates to a method of cell culture for improving cell growth and productivity, in particular in fed-batch culture of mammalian cells at high cell density. The invention further relates to a method of producing cells with improved cell growth and/or productivity in cell culture and to cells obtained or obtainable by such methods.Type: ApplicationFiled: July 12, 2023Publication date: March 21, 2024Applicant: Pfizer Inc.Inventors: Gregory Walter HILLER, Jeffrey Joseph MITCHELL, Bhanu Chandra MULUKUTLA, Pamela Mary PEGMAN
-
Publication number: 20240083991Abstract: Antibodies, and antigen-binding fragments thereof, that specifically bind to bone morphogenetic protein-9 (BMP9) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.Type: ApplicationFiled: May 31, 2023Publication date: March 14, 2024Applicants: Pfizer Inc., The Brigham and Women's Hospital, Inc., The General Hospital CorporationInventors: Paul B. Yu, James Reasoner Apgar, Susan Adam Benard, Stephen Peter Berasi, Christine Huard, Oleg Victorovich Kovalenko, Lidia Mosyak, Xianchun Tang, Kathleen Elisabeth Tumelty, Luca Troncone, Ying Zhong
-
Patent number: 11926636Abstract: This invention relates to new crystalline forms of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile(lorlatinib) maleate. The invention also relates to pharmaceutical compositions comprising lorlatinib maleate, and to methods of using lorlatinib maleate and compositions comprising it in the treatment of abnormal cell growth, such as cancer, in mammals.Type: GrantFiled: July 1, 2021Date of Patent: March 12, 2024Assignee: Pfizer Inc.Inventor: Klimentina Dimitrova Pencheva
-
Patent number: 11926642Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.Type: GrantFiled: July 1, 2021Date of Patent: March 12, 2024Assignee: Pfizer inc.Inventors: Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
-
Publication number: 20240076287Abstract: The invention relates to solid forms of (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}amino)-1H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate, to pharmaceutical compositions comprising such solid forms, and to use of such solid forms and pharmaceutical compositions for the treatment of cancer.Type: ApplicationFiled: December 21, 2021Publication date: March 7, 2024Applicant: PFIZER INC.Inventors: Fengjuan CAO, Kevin Francis DEBOYACE, Michael HEBERLEIN
-
Publication number: 20240076382Abstract: Antibodies, and antigen-binding fragments thereof, that specifically bind to Cluster of Differentiation 1a (CD1a) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.Type: ApplicationFiled: July 19, 2023Publication date: March 7, 2024Applicants: Pfizer Inc., Children's Medical Center CorporationInventors: Florian WINAU, Oleg V. KOVALENKO, Chew Shun CHANG, Di WU, Nicholas Andrew MARZE, Shian-Huey CHIANG
-
Patent number: 11911383Abstract: The present invention relates to an oral solution formulation or an oral powder for constitution comprising 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, or a lactate or malate salt thereof, and a buffer system comprising lactic acid or malic acid.Type: GrantFiled: May 3, 2019Date of Patent: February 27, 2024Assignee: Pfizer Inc.Inventors: Ashwinkumar Jain, Weili Yu
-
Patent number: 11912776Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).Type: GrantFiled: March 15, 2022Date of Patent: February 27, 2024Assignee: PFIZER INC.Inventors: Tracy Chia-Chien Kuo, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
-
Publication number: 20240059679Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.Type: ApplicationFiled: October 9, 2023Publication date: February 22, 2024Applicant: Pfizer Inc.Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
-
Publication number: 20240059799Abstract: The present invention discloses an isolated antibody that specifically binds to TL1A, comprising a heavy chain variable region (TL1A-VH) and a light chain variable region (TL1A-VL), comprising the CDR-H1, CDR-H2, and CDR-H3 sequences of a TL1A-VH sequence selected from the group consisting of SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 57, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 89, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 110, SEQ ID NO: 120; and the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 18.Type: ApplicationFiled: May 9, 2023Publication date: February 22, 2024Applicants: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: James Reasoner APGAR, Laird BLOOM, Fang JIN, Fridrik KARLSSON, Kimberly Ann MARQUETTE, Jessica Haewon MIN DEBARTOLO, Nicole Melissa PICHE-NICHOLAS, Lioudmila TCHISTIAKOVA
-
Patent number: 11905284Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.Type: GrantFiled: June 1, 2021Date of Patent: February 20, 2024Assignee: PFIZER INC.Inventors: Lei Zhang, Christopher Ryan Butler, Elizabeth Mary Beck, Michael Aaron Brodney, Matthew Frank Brown, Laura Ann McAllister, Erik Alphie LaChapelle, Adam Matthew Gilbert
-
Patent number: D1017017Type: GrantFiled: December 20, 2021Date of Patent: March 5, 2024Assignee: Pfizer Inc.Inventors: Patrick David Daugherity, Weili Yu, Daniel R. Arenson